Table 4: Specific reasons for modification
Variable | Frequency (%) |
Toxicity Lipodystrophy Peripheral neuropathy Anaemia Hyper-pigmentation Rashes CNS Side effects Dyslipidemia Renal Failure Lactic Acidosis Hepatotoxicity Convulsive disorder Co-morbid conditions Tuberculosis Pregnancy Hepatitis B co-infection Other New guidelines Lack of stock Regimen simplification |
422 (62.1) 108 (15.9) 60 (8.8) 22 (3.2) 20 (2.9) 14 (2.1) 12 (1.8) 12 (1.8) 4 (0.6) 4 (0.6) 2 (0.3) 52 (54.2) 62 (43.7) 2 (2.1) 82 (72.0) 28 (24.6) 4 (3.5) |